Marian Rewers
Concepts (933)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 397 | 2026 | 3952 | 20.540 |
Why?
| | Autoimmunity | 139 | 2026 | 935 | 12.350 |
Why?
| | Islets of Langerhans | 127 | 2026 | 853 | 12.070 |
Why?
| | Autoantibodies | 193 | 2026 | 1513 | 11.550 |
Why?
| | Celiac Disease | 55 | 2026 | 314 | 7.140 |
Why?
| | Genetic Predisposition to Disease | 97 | 2026 | 2458 | 4.260 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 754 | 3.200 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 267 | 3.000 |
Why?
| | Child, Preschool | 215 | 2026 | 12017 | 2.980 |
Why?
| | HLA-DQ Antigens | 38 | 2025 | 174 | 2.900 |
Why?
| | Child | 248 | 2026 | 22980 | 2.830 |
Why?
| | Calcinosis | 23 | 2015 | 234 | 2.730 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 220 | 2.610 |
Why?
| | Insulin Resistance | 55 | 2018 | 1253 | 2.480 |
Why?
| | Insulin | 76 | 2026 | 2526 | 2.420 |
Why?
| | Infant | 172 | 2026 | 10195 | 2.380 |
Why?
| | Disease Progression | 83 | 2026 | 2892 | 2.350 |
Why?
| | Risk Factors | 167 | 2026 | 11017 | 2.220 |
Why?
| | Diabetic Ketoacidosis | 17 | 2026 | 212 | 2.130 |
Why?
| | Humans | 519 | 2026 | 147306 | 2.100 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2026 | 2223 | 2.010 |
Why?
| | Transglutaminases | 30 | 2026 | 159 | 1.990 |
Why?
| | Genotype | 64 | 2026 | 1875 | 1.970 |
Why?
| | Blood Glucose | 38 | 2022 | 2359 | 1.950 |
Why?
| | Autoimmune Diseases | 17 | 2026 | 471 | 1.930 |
Why?
| | Male | 353 | 2026 | 73954 | 1.890 |
Why?
| | Prospective Studies | 101 | 2026 | 8166 | 1.840 |
Why?
| | Biomarkers | 50 | 2026 | 4354 | 1.830 |
Why?
| | Female | 361 | 2026 | 80081 | 1.830 |
Why?
| | Adolescent | 151 | 2026 | 22826 | 1.820 |
Why?
| | Insulin Antibodies | 24 | 2026 | 103 | 1.820 |
Why?
| | Mass Screening | 25 | 2026 | 1375 | 1.800 |
Why?
| | Glutamate Decarboxylase | 35 | 2025 | 166 | 1.610 |
Why?
| | Hyperglycemia | 11 | 2026 | 381 | 1.560 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 322 | 1.540 |
Why?
| | Diet | 32 | 2026 | 1284 | 1.500 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 393 | 1.450 |
Why?
| | Coronary Disease | 15 | 2010 | 382 | 1.400 |
Why?
| | HLA Antigens | 25 | 2026 | 245 | 1.370 |
Why?
| | Prediabetic State | 14 | 2023 | 251 | 1.370 |
Why?
| | Case-Control Studies | 60 | 2026 | 3660 | 1.360 |
Why?
| | Follow-Up Studies | 66 | 2026 | 5478 | 1.230 |
Why?
| | Health Care Costs | 2 | 2025 | 428 | 1.170 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 48 | 1.160 |
Why?
| | Cohort Studies | 69 | 2026 | 6099 | 1.120 |
Why?
| | Glutens | 11 | 2023 | 62 | 1.120 |
Why?
| | Diabetes Mellitus, Type 2 | 36 | 2025 | 2627 | 1.090 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 145 | 1.060 |
Why?
| | Enterovirus Infections | 6 | 2023 | 175 | 1.030 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 615 | 1.010 |
Why?
| | HLA-DR3 Antigen | 17 | 2025 | 76 | 1.010 |
Why?
| | Environment | 5 | 2018 | 297 | 0.990 |
Why?
| | Adult | 160 | 2026 | 41406 | 0.980 |
Why?
| | DNA Methylation | 8 | 2026 | 722 | 0.960 |
Why?
| | Infant, Newborn | 67 | 2026 | 6543 | 0.960 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 8 | 0.940 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 55 | 0.920 |
Why?
| | Longitudinal Studies | 32 | 2026 | 3029 | 0.890 |
Why?
| | Atherosclerosis | 15 | 2018 | 411 | 0.880 |
Why?
| | HLA-DR4 Antigen | 17 | 2025 | 74 | 0.880 |
Why?
| | Colorado | 45 | 2026 | 4591 | 0.870 |
Why?
| | Incidence | 37 | 2026 | 2954 | 0.830 |
Why?
| | Age of Onset | 20 | 2026 | 568 | 0.830 |
Why?
| | Middle Aged | 137 | 2025 | 36821 | 0.820 |
Why?
| | Diabetes Complications | 7 | 2019 | 225 | 0.810 |
Why?
| | Coronary Vessels | 8 | 2017 | 246 | 0.810 |
Why?
| | Albuminuria | 12 | 2016 | 189 | 0.800 |
Why?
| | Enterovirus | 5 | 2019 | 83 | 0.800 |
Why?
| | Seroconversion | 7 | 2026 | 48 | 0.780 |
Why?
| | Vitamin D | 8 | 2026 | 405 | 0.760 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1344 | 0.760 |
Why?
| | Vascular Calcification | 9 | 2018 | 110 | 0.750 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2133 | 0.710 |
Why?
| | Young Adult | 53 | 2026 | 14437 | 0.690 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 361 | 0.690 |
Why?
| | C-Peptide | 7 | 2025 | 191 | 0.660 |
Why?
| | Breast Feeding | 18 | 2021 | 447 | 0.660 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 54 | 0.650 |
Why?
| | Inflammation | 10 | 2026 | 2921 | 0.640 |
Why?
| | Genetic Testing | 8 | 2019 | 493 | 0.640 |
Why?
| | Haplotypes | 15 | 2026 | 509 | 0.640 |
Why?
| | Fatty Acids | 6 | 2021 | 461 | 0.630 |
Why?
| | Calcium | 8 | 2023 | 1197 | 0.620 |
Why?
| | Zinc Transporter 8 | 8 | 2025 | 70 | 0.620 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 703 | 0.620 |
Why?
| | Early Diagnosis | 8 | 2026 | 254 | 0.610 |
Why?
| | Antibodies, Viral | 6 | 2023 | 687 | 0.600 |
Why?
| | Autoantigens | 9 | 2025 | 429 | 0.590 |
Why?
| | GTP-Binding Proteins | 8 | 2026 | 153 | 0.590 |
Why?
| | Ascorbic Acid | 5 | 2026 | 184 | 0.560 |
Why?
| | Uric Acid | 6 | 2018 | 168 | 0.550 |
Why?
| | Prevalence | 23 | 2024 | 2889 | 0.550 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 159 | 0.540 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 6011 | 0.520 |
Why?
| | Body Mass Index | 23 | 2025 | 2470 | 0.520 |
Why?
| | Germany | 12 | 2024 | 140 | 0.510 |
Why?
| | Logistic Models | 24 | 2017 | 2142 | 0.510 |
Why?
| | Smoking | 9 | 2025 | 1483 | 0.510 |
Why?
| | Infant Food | 7 | 2018 | 69 | 0.510 |
Why?
| | Adiponectin | 5 | 2016 | 244 | 0.500 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 97 | 0.500 |
Why?
| | Sensitivity and Specificity | 22 | 2026 | 2017 | 0.490 |
Why?
| | Edible Grain | 4 | 2008 | 47 | 0.490 |
Why?
| | Finland | 16 | 2025 | 80 | 0.490 |
Why?
| | Fibrinogen | 5 | 2019 | 180 | 0.490 |
Why?
| | Prognosis | 21 | 2026 | 4384 | 0.490 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 765 | 0.480 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 290 | 0.480 |
Why?
| | Metabolomics | 5 | 2021 | 737 | 0.470 |
Why?
| | Age Factors | 38 | 2026 | 3372 | 0.470 |
Why?
| | Arteriosclerosis | 17 | 2004 | 83 | 0.470 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 430 | 0.460 |
Why?
| | Thyroiditis, Autoimmune | 2 | 2026 | 16 | 0.460 |
Why?
| | Genome-Wide Association Study | 10 | 2026 | 1496 | 0.450 |
Why?
| | Hypoglycemia | 5 | 2014 | 489 | 0.450 |
Why?
| | Hypertension | 11 | 2021 | 1280 | 0.440 |
Why?
| | Triglycerides | 13 | 2020 | 529 | 0.440 |
Why?
| | Milk | 7 | 2017 | 119 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 663 | 0.440 |
Why?
| | Luminescent Measurements | 4 | 2021 | 75 | 0.440 |
Why?
| | Lipids | 5 | 2019 | 723 | 0.430 |
Why?
| | Environmental Exposure | 4 | 2025 | 583 | 0.430 |
Why?
| | Probiotics | 3 | 2022 | 61 | 0.420 |
Why?
| | C-Reactive Protein | 5 | 2018 | 430 | 0.420 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.420 |
Why?
| | Helicobacter pylori | 1 | 2014 | 44 | 0.420 |
Why?
| | Risk | 17 | 2020 | 927 | 0.410 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 399 | 0.410 |
Why?
| | Antibodies | 5 | 2024 | 398 | 0.400 |
Why?
| | Micronutrients | 3 | 2026 | 102 | 0.400 |
Why?
| | Time Factors | 21 | 2018 | 7173 | 0.400 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 104 | 0.400 |
Why?
| | Dietary Supplements | 7 | 2024 | 586 | 0.400 |
Why?
| | Inflammation Mediators | 3 | 2026 | 507 | 0.400 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 55 | 0.390 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 32 | 0.390 |
Why?
| | Sweden | 13 | 2024 | 117 | 0.390 |
Why?
| | Immunogenetics | 1 | 2013 | 8 | 0.390 |
Why?
| | Dyslipidemias | 4 | 2015 | 185 | 0.380 |
Why?
| | Alleles | 14 | 2021 | 909 | 0.380 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 199 | 0.380 |
Why?
| | Proteomics | 6 | 2025 | 1205 | 0.370 |
Why?
| | Risk Assessment | 17 | 2021 | 3784 | 0.370 |
Why?
| | HLA-D Antigens | 5 | 2019 | 30 | 0.370 |
Why?
| | Bacteriophages | 2 | 2025 | 110 | 0.370 |
Why?
| | United States | 35 | 2025 | 16313 | 0.370 |
Why?
| | Dietary Fats | 3 | 2014 | 309 | 0.360 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 106 | 0.360 |
Why?
| | Oxylipins | 3 | 2023 | 47 | 0.360 |
Why?
| | Fasting | 12 | 2015 | 280 | 0.360 |
Why?
| | Cost-Benefit Analysis | 4 | 2026 | 654 | 0.360 |
Why?
| | Genetic Variation | 4 | 2026 | 995 | 0.350 |
Why?
| | Epitopes | 6 | 2025 | 475 | 0.350 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 190 | 0.350 |
Why?
| | Lipoproteins | 4 | 2015 | 166 | 0.350 |
Why?
| | Apolipoproteins A | 2 | 2006 | 19 | 0.350 |
Why?
| | Addison Disease | 6 | 2012 | 38 | 0.340 |
Why?
| | Major Histocompatibility Complex | 6 | 2026 | 234 | 0.340 |
Why?
| | Liver | 3 | 2012 | 1916 | 0.330 |
Why?
| | Fetal Blood | 6 | 2021 | 327 | 0.330 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Sex Factors | 20 | 2020 | 2136 | 0.320 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 89 | 0.320 |
Why?
| | Dietary Proteins | 4 | 2019 | 135 | 0.320 |
Why?
| | Life Style | 5 | 2015 | 504 | 0.320 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 742 | 0.320 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1415 | 0.320 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 202 | 0.310 |
Why?
| | Plant Proteins | 1 | 2011 | 111 | 0.310 |
Why?
| | Epidemics | 1 | 2011 | 96 | 0.310 |
Why?
| | Eating | 5 | 2023 | 387 | 0.310 |
Why?
| | Precision Medicine | 1 | 2014 | 464 | 0.310 |
Why?
| | Research | 2 | 2013 | 435 | 0.310 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 6164 | 0.300 |
Why?
| | Blood Proteins | 3 | 2017 | 239 | 0.300 |
Why?
| | Patient Education as Topic | 2 | 2005 | 781 | 0.300 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.300 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 58 | 0.300 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 107 | 0.290 |
Why?
| | Cystatin C | 6 | 2014 | 66 | 0.290 |
Why?
| | Cesarean Section | 2 | 2024 | 230 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1162 | 0.290 |
Why?
| | Family Health | 8 | 2017 | 195 | 0.290 |
Why?
| | Obesity | 12 | 2015 | 3149 | 0.290 |
Why?
| | Cytokines | 6 | 2026 | 2087 | 0.290 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1550 | 0.290 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1072 | 0.280 |
Why?
| | Sex Distribution | 6 | 2011 | 390 | 0.280 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 39 | 0.280 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 773 | 0.280 |
Why?
| | Rotavirus | 2 | 2016 | 21 | 0.280 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.270 |
Why?
| | Feces | 7 | 2025 | 500 | 0.270 |
Why?
| | Antigens, CD | 2 | 2009 | 562 | 0.270 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1107 | 0.270 |
Why?
| | Europe | 11 | 2021 | 426 | 0.260 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.260 |
Why?
| | Adiposity | 7 | 2020 | 533 | 0.260 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.260 |
Why?
| | Epigenesis, Genetic | 4 | 2026 | 708 | 0.260 |
Why?
| | Reference Values | 10 | 2012 | 800 | 0.260 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 172 | 0.260 |
Why?
| | Pregnancy | 18 | 2025 | 7276 | 0.260 |
Why?
| | Carotenoids | 2 | 2026 | 47 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2791 | 0.250 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 59 | 0.250 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 185 | 0.250 |
Why?
| | Proteome | 2 | 2025 | 520 | 0.250 |
Why?
| | Iron | 3 | 2023 | 361 | 0.250 |
Why?
| | Survival Analysis | 4 | 2021 | 1386 | 0.250 |
Why?
| | Adipose Tissue | 4 | 2018 | 646 | 0.250 |
Why?
| | Glycopeptides | 2 | 2018 | 48 | 0.250 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 110 | 0.240 |
Why?
| | Metabolome | 2 | 2020 | 391 | 0.240 |
Why?
| | Patient Compliance | 3 | 2023 | 591 | 0.240 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.240 |
Why?
| | Rotavirus Infections | 1 | 2006 | 37 | 0.240 |
Why?
| | RNA, Viral | 3 | 2019 | 695 | 0.240 |
Why?
| | Tocopherols | 1 | 2026 | 31 | 0.240 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 207 | 0.240 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.240 |
Why?
| | Remission Induction | 2 | 2004 | 310 | 0.240 |
Why?
| | Exercise | 4 | 2023 | 2219 | 0.240 |
Why?
| | HLA-DR alpha-Chains | 1 | 2026 | 5 | 0.240 |
Why?
| | Complement C4a | 1 | 2026 | 9 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 230 | 0.240 |
Why?
| | Overweight | 3 | 2021 | 617 | 0.230 |
Why?
| | Vitamin A | 1 | 2026 | 62 | 0.230 |
Why?
| | Regression Analysis | 15 | 2014 | 1003 | 0.230 |
Why?
| | Infant Formula | 3 | 2019 | 71 | 0.230 |
Why?
| | Contraception | 1 | 2008 | 170 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 167 | 0.230 |
Why?
| | Thyroid Gland | 1 | 2026 | 93 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.230 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2218 | 0.230 |
Why?
| | Chromosome Mapping | 4 | 2025 | 512 | 0.230 |
Why?
| | Carotid Arteries | 5 | 1998 | 208 | 0.220 |
Why?
| | Hypersensitivity, Immediate | 1 | 2025 | 41 | 0.220 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 389 | 0.220 |
Why?
| | Maternal Age | 3 | 2004 | 129 | 0.220 |
Why?
| | Gene Frequency | 10 | 2020 | 498 | 0.220 |
Why?
| | Diet Records | 4 | 2019 | 89 | 0.220 |
Why?
| | Proinsulin | 3 | 2014 | 54 | 0.220 |
Why?
| | Aged | 45 | 2021 | 26516 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 364 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 227 | 0.220 |
Why?
| | Glucose Intolerance | 7 | 2013 | 142 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 85 | 0.220 |
Why?
| | Apolipoproteins | 3 | 2014 | 38 | 0.220 |
Why?
| | Introns | 1 | 2026 | 260 | 0.210 |
Why?
| | Mass Spectrometry | 4 | 2025 | 728 | 0.210 |
Why?
| | Linear Models | 7 | 2016 | 852 | 0.210 |
Why?
| | Abdominal Wall | 1 | 2004 | 28 | 0.210 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 90 | 0.210 |
Why?
| | Health Surveys | 3 | 2018 | 522 | 0.210 |
Why?
| | Immunotherapy | 1 | 2009 | 672 | 0.210 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 522 | 0.210 |
Why?
| | Hyperlipidemias | 1 | 2005 | 120 | 0.210 |
Why?
| | Immunoglobulin A | 6 | 2024 | 214 | 0.200 |
Why?
| | Iodide Peroxidase | 6 | 2026 | 35 | 0.200 |
Why?
| | Bone Density | 2 | 2020 | 493 | 0.200 |
Why?
| | Fever | 1 | 2025 | 320 | 0.200 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 164 | 0.200 |
Why?
| | Vitamin B Complex | 1 | 2024 | 39 | 0.200 |
Why?
| | Seasons | 5 | 2024 | 540 | 0.200 |
Why?
| | Coronary Angiography | 2 | 2014 | 329 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Animals | 26 | 2022 | 38417 | 0.200 |
Why?
| | Peptide Library | 1 | 2024 | 91 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2015 | 151 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 849 | 0.200 |
Why?
| | Haptoglobins | 3 | 2013 | 71 | 0.200 |
Why?
| | Birth Weight | 4 | 2016 | 522 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.190 |
Why?
| | Iron Overload | 1 | 2023 | 19 | 0.190 |
Why?
| | Child Development | 2 | 2020 | 484 | 0.190 |
Why?
| | Virus Diseases | 4 | 2021 | 218 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1798 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 175 | 0.190 |
Why?
| | ROC Curve | 4 | 2019 | 626 | 0.180 |
Why?
| | Ketone Bodies | 2 | 2014 | 16 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 975 | 0.180 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 221 | 0.180 |
Why?
| | Influenza, Human | 2 | 2022 | 634 | 0.180 |
Why?
| | Alcohol Drinking | 1 | 2009 | 858 | 0.180 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 211 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 448 | 0.180 |
Why?
| | Mothers | 4 | 2021 | 774 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 322 | 0.180 |
Why?
| | Pediatrics | 4 | 2020 | 1139 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 178 | 0.180 |
Why?
| | Lipid Metabolism | 2 | 2019 | 538 | 0.170 |
Why?
| | Peptides | 3 | 2024 | 1003 | 0.170 |
Why?
| | Bacteria | 2 | 2025 | 769 | 0.170 |
Why?
| | Blood Pressure | 9 | 2014 | 1785 | 0.170 |
Why?
| | Age Distribution | 5 | 2011 | 406 | 0.170 |
Why?
| | Odds Ratio | 6 | 2015 | 1084 | 0.170 |
Why?
| | T-Lymphocytes | 3 | 2025 | 2017 | 0.170 |
Why?
| | Lipase | 1 | 2002 | 76 | 0.170 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 14 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 49 | 0.170 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 89 | 0.170 |
Why?
| | Parents | 6 | 2023 | 1428 | 0.170 |
Why?
| | Glycerol | 2 | 2012 | 90 | 0.170 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 56 | 0.170 |
Why?
| | Growth | 2 | 2016 | 49 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1253 | 0.170 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3448 | 0.170 |
Why?
| | Body Height | 3 | 2014 | 205 | 0.170 |
Why?
| | Polysaccharides | 2 | 2022 | 89 | 0.160 |
Why?
| | White Matter | 1 | 2023 | 170 | 0.160 |
Why?
| | Gastroenteritis | 2 | 2016 | 63 | 0.160 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 21 | 0.160 |
Why?
| | Gestational Age | 3 | 2020 | 997 | 0.160 |
Why?
| | Luminescence | 3 | 2016 | 37 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2026 | 878 | 0.160 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 11 | 0.160 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.160 |
Why?
| | Vitamins | 2 | 2020 | 184 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2017 | 541 | 0.160 |
Why?
| | Neutrophils | 1 | 2026 | 1135 | 0.160 |
Why?
| | Genomics | 2 | 2021 | 839 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 347 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 147 | 0.150 |
Why?
| | Dietary Sucrose | 1 | 2020 | 50 | 0.150 |
Why?
| | Biopsy | 5 | 2017 | 1093 | 0.150 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.150 |
Why?
| | Sugars | 1 | 2020 | 40 | 0.150 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 21 | 0.150 |
Why?
| | Neonatal Screening | 4 | 2020 | 185 | 0.150 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 126 | 0.150 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 616 | 0.150 |
Why?
| | Life Change Events | 1 | 2021 | 149 | 0.150 |
Why?
| | Energy Intake | 5 | 2023 | 514 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 786 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 83 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.150 |
Why?
| | Kidney | 2 | 2018 | 1511 | 0.150 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 115 | 0.150 |
Why?
| | Developing Countries | 2 | 1993 | 318 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2017 | 1368 | 0.150 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 91 | 0.150 |
Why?
| | Measles | 1 | 2019 | 46 | 0.140 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 120 | 0.140 |
Why?
| | Apolipoproteins B | 2 | 2015 | 48 | 0.140 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 62 | 0.140 |
Why?
| | Glycosuria | 2 | 2009 | 10 | 0.140 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 47 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 442 | 0.140 |
Why?
| | Butyrates | 1 | 2019 | 66 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 148 | 0.140 |
Why?
| | Cotinine | 1 | 2019 | 77 | 0.140 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 77 | 0.140 |
Why?
| | Uromodulin | 1 | 2018 | 22 | 0.140 |
Why?
| | Genetic Markers | 4 | 2013 | 338 | 0.140 |
Why?
| | Cholesterol | 5 | 2014 | 410 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 254 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 119 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1772 | 0.140 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 88 | 0.130 |
Why?
| | Health Expenditures | 1 | 2020 | 199 | 0.130 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2134 | 0.130 |
Why?
| | Self Report | 3 | 2020 | 887 | 0.130 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 8 | 0.130 |
Why?
| | Squalene | 1 | 2017 | 9 | 0.130 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 375 | 0.130 |
Why?
| | Phenotype | 8 | 2024 | 3216 | 0.130 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 178 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1794 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 327 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 165 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 55 | 0.130 |
Why?
| | Feeding Behavior | 3 | 2013 | 693 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 694 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 536 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 178 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2019 | 371 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 386 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 239 | 0.120 |
Why?
| | Genetic Loci | 3 | 2015 | 272 | 0.120 |
Why?
| | Kidney Diseases | 2 | 2012 | 428 | 0.120 |
Why?
| | Rural Health | 2 | 2002 | 87 | 0.120 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 55 | 0.120 |
Why?
| | Poland | 4 | 2010 | 34 | 0.120 |
Why?
| | Models, Theoretical | 2 | 2017 | 563 | 0.120 |
Why?
| | Milk Proteins | 1 | 1996 | 33 | 0.120 |
Why?
| | Body Weight | 3 | 2016 | 976 | 0.120 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.120 |
Why?
| | Homozygote | 5 | 2014 | 199 | 0.120 |
Why?
| | Arachidonic Acid | 2 | 2021 | 102 | 0.120 |
Why?
| | Immunoglobulin G | 4 | 2021 | 901 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1024 | 0.120 |
Why?
| | Patient Care Planning | 2 | 2015 | 171 | 0.120 |
Why?
| | Hygiene | 1 | 2016 | 29 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2017 | 139 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 3 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 44 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 32 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 91 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1046 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 82 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 131 | 0.110 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 751 | 0.110 |
Why?
| | Feeding Methods | 1 | 2015 | 5 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1598 | 0.110 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 123 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 539 | 0.110 |
Why?
| | Medical Records | 2 | 2007 | 192 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 277 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2021 | 1174 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 188 | 0.110 |
Why?
| | Genetic Association Studies | 4 | 2020 | 374 | 0.110 |
Why?
| | Carbohydrates | 1 | 2015 | 66 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2015 | 59 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 673 | 0.110 |
Why?
| | Child Day Care Centers | 1 | 2015 | 44 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 998 | 0.110 |
Why?
| | Erythrocytes | 1 | 2021 | 749 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 848 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 30 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 11 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 27 | 0.100 |
Why?
| | Dairy Products | 1 | 2014 | 30 | 0.100 |
Why?
| | Genetic Linkage | 2 | 2015 | 273 | 0.100 |
Why?
| | Video Recording | 2 | 2015 | 222 | 0.100 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.100 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2886 | 0.100 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 70 | 0.100 |
Why?
| | Societies, Scientific | 1 | 2014 | 50 | 0.100 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 80 | 0.100 |
Why?
| | Acetaminophen | 1 | 2017 | 269 | 0.100 |
Why?
| | Bias | 1 | 2015 | 201 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2016 | 172 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 347 | 0.100 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 37 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 15 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1481 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 25 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1127 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 197 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 177 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 516 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 323 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 679 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2013 | 83 | 0.090 |
Why?
| | Heart Rate | 3 | 2010 | 860 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 166 | 0.090 |
Why?
| | Mice | 11 | 2022 | 18493 | 0.090 |
Why?
| | Hypoxia | 1 | 2020 | 1209 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 27 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2013 | 119 | 0.090 |
Why?
| | Anesthesiology | 1 | 2015 | 179 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2022 | 840 | 0.090 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 137 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 227 | 0.090 |
Why?
| | Stomach | 1 | 2012 | 111 | 0.090 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 65 | 0.090 |
Why?
| | CpG Islands | 2 | 2023 | 176 | 0.090 |
Why?
| | Sex Characteristics | 7 | 2015 | 799 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 207 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 378 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1912 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 333 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 183 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 102 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 50 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 115 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 168 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 356 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 915 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 522 | 0.080 |
Why?
| | Gliadin | 2 | 2009 | 13 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1281 | 0.080 |
Why?
| | Primary Prevention | 1 | 2013 | 228 | 0.080 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 193 | 0.080 |
Why?
| | Vaccines | 1 | 2016 | 389 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2012 | 440 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 58 | 0.080 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 24 | 0.080 |
Why?
| | Patient Selection | 3 | 2011 | 746 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2011 | 156 | 0.080 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 16 | 0.080 |
Why?
| | Viruses | 1 | 2013 | 166 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2030 | 0.080 |
Why?
| | Thyroglobulin | 3 | 2025 | 29 | 0.080 |
Why?
| | Vascular Diseases | 2 | 2013 | 252 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Food, Fortified | 1 | 2010 | 44 | 0.080 |
Why?
| | Weight Gain | 2 | 2011 | 566 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 259 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 736 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 222 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 394 | 0.080 |
Why?
| | Milk, Human | 3 | 2018 | 176 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 91 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 154 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1140 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 480 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1213 | 0.080 |
Why?
| | RNA | 1 | 2016 | 916 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 590 | 0.070 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1342 | 0.070 |
Why?
| | Membrane Proteins | 3 | 2002 | 1171 | 0.070 |
Why?
| | Family | 5 | 2018 | 690 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2026 | 1147 | 0.070 |
Why?
| | Quality Control | 3 | 2013 | 161 | 0.070 |
Why?
| | Transcription Factors | 1 | 2017 | 1747 | 0.070 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.070 |
Why?
| | Pancreas | 2 | 2023 | 345 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 780 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 365 | 0.070 |
Why?
| | Bifidobacterium | 2 | 2018 | 21 | 0.070 |
Why?
| | Homeostasis | 2 | 2010 | 651 | 0.070 |
Why?
| | Antigens, Viral | 2 | 2021 | 186 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 296 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 104 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 26 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1868 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 509 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 627 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 84 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 347 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 784 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 111 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 420 | 0.060 |
Why?
| | Telomere | 3 | 2022 | 299 | 0.060 |
Why?
| | Antibody Formation | 1 | 2008 | 288 | 0.060 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 119 | 0.060 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 97 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 57 | 0.060 |
Why?
| | Clinical Competence | 1 | 2015 | 1260 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 575 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 245 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1940 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 121 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 159 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 486 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 171 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 961 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 640 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 488 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 180 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 11 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 536 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 61 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 15 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 15 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 151 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 445 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 43 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 79 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 26 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1845 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 430 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 453 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2026 | 95 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 76 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 303 | 0.060 |
Why?
| | Health Plan Implementation | 1 | 2026 | 142 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 45 | 0.050 |
Why?
| | Capsid Proteins | 1 | 2005 | 94 | 0.050 |
Why?
| | Protective Factors | 2 | 2015 | 102 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2026 | 132 | 0.050 |
Why?
| | Fathers | 1 | 2005 | 53 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 149 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 512 | 0.050 |
Why?
| | Norway | 2 | 2019 | 41 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 948 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1158 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 113 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4605 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 353 | 0.050 |
Why?
| | Survivors | 1 | 2008 | 528 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 64 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 127 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 206 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 138 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 146 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 394 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1059 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1444 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 22 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 84 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 330 | 0.050 |
Why?
| | Registries | 7 | 2019 | 2434 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 198 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 334 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 23 | 0.050 |
Why?
| | Computer Simulation | 2 | 2026 | 1018 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 273 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 88 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 63 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 723 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 132 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 134 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 358 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 17 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 467 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3153 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 675 | 0.040 |
Why?
| | Choline | 1 | 2023 | 138 | 0.040 |
Why?
| | Candida | 1 | 2022 | 46 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 482 | 0.040 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 12 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2026 | 322 | 0.040 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.040 |
Why?
| | Prenatal Care | 1 | 2004 | 310 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 70 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 525 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 20 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 417 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 122 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | China | 1 | 2021 | 278 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 105 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Perception | 1 | 2023 | 378 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 119 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 17561 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 33 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 789 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 153 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 677 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 12 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 39 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 16 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 353 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 168 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 20 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 732 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 28 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 62 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 58 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 79 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 597 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 29 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 204 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 48 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 27 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 267 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 183 | 0.040 |
Why?
| | Proline | 1 | 2020 | 82 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 121 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 28 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 43 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 103 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 125 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 161 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 316 | 0.040 |
Why?
| | Texas | 2 | 2014 | 278 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 187 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 93 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 593 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 84 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 428 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 16 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 199 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1599 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 596 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 173 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 48 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.030 |
Why?
| | Down-Regulation | 1 | 2021 | 618 | 0.030 |
Why?
| | Pets | 1 | 2018 | 28 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 318 | 0.030 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2018 | 80 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 60 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2000 | 248 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 195 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 43 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 444 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 379 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Employment | 1 | 2020 | 184 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 135 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2974 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 259 | 0.030 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 39 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 144 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 35 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 460 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 45 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 372 | 0.030 |
Why?
| | Canada | 1 | 2018 | 435 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 126 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 186 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 48 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 502 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 70 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 313 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 178 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 14 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 391 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 39 | 0.030 |
Why?
| | Africa | 2 | 1996 | 119 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 654 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 514 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 85 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 15 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 162 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1149 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 313 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 16 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 310 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 322 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1266 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1302 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 84 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 779 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 499 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 80 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 505 | 0.030 |
Why?
| | Genes | 1 | 1995 | 230 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 36 | 0.030 |
Why?
| | Florida | 1 | 2015 | 118 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 441 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 317 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 745 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 3246 | 0.030 |
Why?
| | Washington | 1 | 2015 | 157 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 240 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 334 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 82 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 703 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 387 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 65 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 145 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 79 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 88 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 151 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 10 | 0.020 |
Why?
| | Family Characteristics | 1 | 2015 | 203 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 49 | 0.020 |
Why?
| | Asthma | 1 | 2025 | 1805 | 0.020 |
Why?
| | Hospitalization | 1 | 2004 | 2496 | 0.020 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 61 | 0.020 |
Why?
| | Base Sequence | 2 | 2011 | 2175 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 311 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 171 | 0.020 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 12 | 0.020 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 9 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 119 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 35 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 70 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 66 | 0.020 |
Why?
| | California | 2 | 2004 | 477 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1672 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 104 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 155 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 149 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 329 | 0.020 |
Why?
| | Genome | 1 | 2014 | 306 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 79 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1992 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 97 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 924 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 90 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 15 | 0.020 |
Why?
| | Observation | 1 | 2011 | 54 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 6 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 933 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 148 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 159 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 31 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 51 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 387 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1518 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 30 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 138 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 332 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.020 |
Why?
| | Causality | 1 | 1991 | 129 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 914 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 249 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 698 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 590 | 0.020 |
Why?
| | Brain | 1 | 2023 | 3009 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 959 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 12 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 19 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 29 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 53 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 251 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 153 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 414 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 4 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8432 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 528 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 103 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 43 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1443 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 862 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 19 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 38 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 136 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 2110 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 19 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 980 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 32 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 37 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 201 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 5 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 8 | 0.020 |
Why?
| | Probability | 1 | 1989 | 309 | 0.020 |
Why?
| | Americas | 1 | 1988 | 27 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 450 | 0.020 |
Why?
| | Asia | 1 | 1988 | 70 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 114 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 123 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 175 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 162 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1730 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 60 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 74 | 0.010 |
Why?
| | Protein Array Analysis | 1 | 2006 | 56 | 0.010 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 51 | 0.010 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 62 | 0.010 |
Why?
| | Serotyping | 1 | 2005 | 31 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1514 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 362 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 395 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2812 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 547 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 475 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 369 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 149 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 64 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 180 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 795 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 124 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 11947 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 216 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 93 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 198 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4130 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 357 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 44 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 319 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2197 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 268 | 0.010 |
Why?
| | Health | 1 | 2003 | 82 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 80 | 0.010 |
Why?
| | Income | 1 | 2003 | 208 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 52 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 99 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 225 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4170 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 45 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 32 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 273 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 514 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1049 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 82 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 108 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5272 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 133 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 165 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 282 | 0.010 |
Why?
| | Demography | 1 | 1998 | 283 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1183 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 116 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2625 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 363 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 247 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 422 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 233 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2542 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1188 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5613 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 937 | 0.010 |
Why?
| | Geography | 1 | 1992 | 187 | 0.010 |
Why?
| | Software | 1 | 1997 | 683 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 5 | 0.000 |
Why?
| | Periodicity | 1 | 1990 | 58 | 0.000 |
Why?
| | Space-Time Clustering | 1 | 1989 | 3 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 16 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 23 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 382 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2946 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|